Urteste S.A. (WSE:URT)

Poland flag Poland · Delayed Price · Currency is PLN
37.90
+3.00 (8.60%)
Oct 10, 2025, 5:00 PM CET
8.60%
Market Cap53.43M
Revenue (ttm)1.80M
Net Income (ttm)-4.16M
Shares Out1.41M
EPS (ttm)-2.95
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,312
Average Volume649
Open35.80
Previous Close34.90
Day's Range33.50 - 39.90
52-Week Range32.50 - 106.00
Beta-0.13
RSI30.85
Earnings DateSep 29, 2025

About Urteste

Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, stomach, lung, oesophagus, ovary, endometrium, blood, breast, and nervous system cancer. The company was incorporated in 2021 and is based in Gdansk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 20
Stock Exchange Warsaw Stock Exchange
Ticker Symbol URT
Full Company Profile

Financial Performance

In 2024, Urteste's revenue was 1.80 million, an increase of 35.34% compared to the previous year's 1.33 million. Losses were -3.63 million, -35.00% less than in 2023.

Financial Statements

News

There is no news available yet.